Successful Use of Levosimendan in a Patient with Peripartum Cardiomyopathy

Anesthesia and Analgesia

Volumn 98, Issue 3, 2004, Pages 822-824

  Benlolo, Sidney ^a   Lefoll, Cécile ^a   Katchatouryan, Vahan ^a   Payen, Didier ^a   Mebazaa, Alexandre ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE; DOBUTAMINE; FUROSEMIDE; LEVOSIMENDAN; LOOP DIURETIC AGENT; NITRATE; SUFENTANIL;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HEART RATE; HUMAN; INTENSIVE CARE; PERIPARTUM CARDIOMYOPATHY; PREGNANCY COMPLICATION; PRIMIGRAVIDA; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VAGINAL DELIVERY;

EID: 1342267272     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000099717.40471.83     Document Type: Article

References (14)

1. Beus E, Mook W, Ramsay G, et al. Peripartum cardiomyopathy: a condition intensivists should be aware of. Intensive Care Med 2003;29:167-74.
2. Gilles A, Antoine M, Vincent J, Kleeman U. Peripartum cardiomyopathy. Rev Med Brux 2001;22:436-8.
3. Heider A, Kuller J, Strauss R, Wells S. Peripartum cardiomyopathy: a review of the literature. Obstet Gynecol Surv 1999;54:526-31.
4. Moiseyev V, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction (a randomised, placebo-controlled, double-blind study; RUSSLAN). Eur Heart J 2002;23:1422-32.
5. Follath F, Cleland J, Just H, et al. Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
6. Slawsky MT, Colucci WS, Gottlieb SS. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-7.
7. Pearson G, Veille J, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (NIH) workshop recommendations and review. JAMA 2000;283:1183-88.
8. Lampert M, Lang R. Peripartum cardiomyopathy. Am Heart J 1995;130:860-70.
9. Malinow A, Butterworth J, Johnson M, et al. Peripartum cardiomyopathy presenting at Cesarean delivery. Anesthesiology 1985;63:545-7.
10. Lu J, Manullang T, Staples M, et al. Maternal respiratory arrests, severe hypotension, and fetal distress after administration of intrathecal sufentanil and bupivacaine after intravenous fentanyl. Anesthesiology 1997;87:170-2.
11. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth 2001;48:88-98.
12. Lehtonen L. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001;10:955-70.
13. Cleland J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiology 2002;17:257-65.
14. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Pharmacol Ther 2002;40:465-71.